Article Sidebar

PDF (Tiếng Việt)
Published: 2022-08-31
Abstract Views: 191
Views PDF (Tiếng Việt): 160
DOI: https://doi.org/10.52852/tcncyh.v156i8.1004
Issue
Vol. 156 No. 8 (2022)
Section
Các bài báo
How to Cite
Xuân, N. T., Giao, N. Q. ., Chiều, T. V., Nam, L. H., Dung, Đặng T. N., & Chi, T. K. (2022). 4. Single nucleotide polymorphism of the oprd1 in treatment in opioid-dependent patients. Journal of Medical Research, 156(8), 28-34. https://doi.org/10.52852/tcncyh.v156i8.1004

4. Single nucleotide polymorphism of the oprd1 in treatment in opioid-dependent patients

Nguyen Thi Xuan1, Nguyen Quynh Giao, Tran Van Chieu, Le Hoang Nam, Dang Thi Ngoc Dung, Tran Khanh Chi2
1 Đại học y Hà Nội
2 Ha Noi Medical University

Main Article Content

Abstract

This study is to describe the distribution of the OPRD1 gene at SNP rs2234918, SNP rs581111, SNP rs529520 and evaluate its correlation with methadone dose in methadone maintenance therapy at Ninh Binh province. We performed a cross-sectional descriptive study of 400 patients diagnosed with dependence on opiate substances and receiving methadone maintenance treatment from March 2021 to May 2022. Single nucleotide polymorphism of the OPRD1 identified by PCR and sequencing results in: SNP rs2234918: the proportion of allele A and allele C are 69.38% and 30,62% respectively; TT genotype (48.5%), CT genotype (41.75%), CC genotype (9,75%). SNP rs581111: the proportion of allele G and allele A are 88,62% v‡ 11,38% respectively; GG genotype (79.00%), AG genotype (19.25%), AA genotype (1,75%). SNP rs529520: the proportion of allele C and allele A are 15,38% v‡ 84,62% respectively; CC genotype (73.00%), AC genotype (23,25%), AA genotype (3,75%). Opioid-dependent patients carrying allele C in SNP rs2234918 are more likely to use a high maintenance dose of methadone (≥ 90 mg/day) than those without allele C with OR = 1.556 (95%CI: 1,049-2,309). Opioid-dependent patients carrying TT genotype in SNP rs2234918 are less likely to use a high maintenance dose of methadone (≥ 90 mg/day) than those without TT genotype with OR= 0,643 (95%CI: 0,433-0,953). The identification of the genotype in the OPRD1 gene in opioid- dependent patients in methadone maintenance treatment may facilitate individualization of treatment.

Article Details

Keywords

Addiction to opiates, methadone maintenance treatment (MMT), individualization of treatment, OPRD1 gene, OPRD1 gene, SNP rs2234918, SNP rs529520, SNP rs581111

References

1. Niaz K. International drug control system and the United Nations General Assembly Special Session (UNGASS) on the world drug problem: an overview. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2017; 23(3): 143-149.
2. Clarke TK, Crist RC, Ang A, et al. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. The pharmacogenomics journal. 2014; 14(3): 303-308.
3. Crist RC, Clarke TK. OPRD1 Genetic Variation and Human Disease. Handbook of experimental pharmacology. 2018; 247: 131-145.
4. Nelson EC, Lynskey MT, Heath AC, et al. Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. Addiction biology. 2014; 19(1): 111-121.
5. Luo R, Li X, Qin S, et al. Impact of SNP-SNP interaction among ABCB1, ARRB2, DRD1 and OPRD1 on methadone dosage requirement in Han Chinese patients. Pharmacogenomics. 2017; 18(18): 1659-1670.
6. Mayer P, Rochlitz H, Rauch E, et al. Association between a delta opioid receptor gene polymorphism and heroin dependence in man. Neuroreport. 1997; 8(11):2547-2550.